Biopharma company Allergan has reported stellar fourth-quarter adjusted earnings. The company also revealed that the first of two key trials for its migraine treatment ubrogepant were successful. For the fourth quarter, Allergan reported EPS of $4.86 while analysts had been calling for $4.74. Revenue at $4.33 billion was also ahead of the $4.28 billion that … Continue reading “Allergan Smashes in its Earnings Report”
